PONATINIB-3001:A phase 3, randomized, open-label, multicenter study comparing ponatinib versus imatinib, administered in combination with reduced-intensity chemotherapy, in patients with newly diagnosed philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL)